Long-term results of immunochemotherapy for advanced ovarian cancer.
Fifty-one patients with stage III and IV ovarian adenocarcinoma underwent initial cytoreductive surgery at Kurume University Hospital between January 1982 and October 1985. They were assigned postoperatively by randomized trials to immunochemotherapy or chemotherapy alone. Of all 51 patients, long-term results of immunochemotherapy for 43 patients were evaluated versus radicality of initial cytoreductive surgery. As a result, the group of patients treated with immunochemotherapy tended to have a better prognosis than the group of patients treated with chemotherapy alone, whereas no statistical difference was observed between the two groups. Moreover, no significant difference was observed in the monitoring of OKT 4/8 ratio between the two groups. However, immunochemotherapy produced a favorable prognosis in the patients with residual disease of greater than 2 cm in diameter at initial surgery. In conclusion, these data suggested that immunochemotherapy may have some impact on survival of patients with ovarian adenocarcinoma.
Nishimura
H
H
Department of Obstetrics and Gynecology, Kurume University School of Medicine, Japan.
Hamaguchi
K
K
Iwanaga
S
S
Tateno
N
N
Akizuki
H
H
Ide
H
H
Yakushiji
M
M
D000230:Adenocarcinoma / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010844:Picibanil / Q000627:therapeutic use*
D010844:Picibanil